NCT05013424

A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines

A Phase 2a Multicenter Open-label Study to Evaluate the Safety and Efficacy of OnabotulinumtoxinA X in Subjects With Glabellar Lines

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 92 (actual)
• Sponsor: Allergan · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Hyperfunctional facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin. BOTOX (onabotulinumtoxinA) was first approved for aesthetic treatment of glabellar lines in 2001 and is one of the most common nonsurgical procedures in aesthetic medicine. This is a proof-of-concept study to evaluate how safe this new OnabotA X formulation is in treating adult participants with GL . OnabotA X is an onabotulinumtoxinA investigational product being developed for the treatment of moderate to severe glabellar lines (GL). This is a 180-day, open-label study to assess the safety of a single dose of 3 different formulations of OnabotA X (A, B \& C; each with varying amounts of the standard excipients in the formulation) in adult subjects with moderate to severe GL. Around 90 participants will be enrolled in the study in approximately 5 sites in the United States. Participants will receive one dose of OnabotA X administered as 5 injections on Day 1. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

• Glabellar Lines

Interventions

Type	Name	Description
DRUG	Formulation A: OnabotulinumtoxinA	Intramuscular Injection
DRUG	Formulation B: OnabotulinumtoxinA	Intramuscular Injection
DRUG	Formulation C: OnabotulinumtoxinA	Intramuscular Injection

Timeline

• Start date: 2021-09-01
• Primary completion: 2022-07-07
• Completion: 2022-07-07
• First posted: 2021-08-19
• Last updated: 2025-06-27
• Results posted: 2025-06-27

Locations

5 sites across 1 country: United States

Regulatory

• FDA-regulated drug study